Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
BLUE bluebird bio, Inc. daily Stock Chart
BLUE [NASD]
bluebird bio, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-8.19 Insider Own0.70% Shs Outstand53.60M Perf Week4.80%
Market Cap7.34B Forward P/E- EPS next Y-11.52 Insider Trans-21.63% Shs Float53.60M Perf Month12.30%
Income-417.80M PEG- EPS next Q-2.86 Inst Own- Short Float9.88% Perf Quarter13.93%
Sales39.50M P/S185.94 EPS this Y25.40% Inst Trans8.74% Short Ratio7.77 Perf Half Y-11.19%
Book/sh37.55 P/B3.65 EPS next Y-6.90% ROA-26.60% Target Price179.39 Perf Year-33.88%
Cash/sh31.63 P/C4.33 EPS next 5Y- ROE-31.50% 52W Range87.49 - 236.17 Perf YTD38.14%
Dividend- P/FCF- EPS past 5Y17.50% ROI-12.70% 52W High-41.98% Beta2.60
Dividend %- Quick Ratio13.10 Sales past 5Y153.30% Gross Margin- 52W Low56.62% ATR5.28
Employees659 Current Ratio13.10 Sales Q/Q49.40% Oper. Margin- RSI (14)63.85 Volatility2.34% 4.18%
OptionableYes Debt/Eq0.08 EPS Q/Q-58.20% Profit Margin- Rel Volume0.67 Prev Close134.29
ShortableYes LT Debt/Eq0.08 EarningsFeb 27 AMC Payout- Avg Volume681.32K Price137.03
Recom1.90 SMA204.97% SMA5018.40% SMA200-5.65% Volume454,026 Change2.04%
Dec-20-18Initiated Raymond James Strong Buy $165
Dec-06-18Downgrade Piper Jaffray Overweight → Neutral
Nov-14-18Upgrade Bernstein Mkt Perform → Outperform
Nov-05-18Upgrade Janney Neutral → Buy
Nov-02-18Upgrade Cantor Fitzgerald Underweight → Neutral $122 → $134
Jul-12-18Initiated Gabelli & Co Buy $239
Jun-19-18Upgrade Evercore ISI In-line → Outperform
Mar-21-18Reiterated Morgan Stanley Equal-Weight $152 → $209
Mar-14-18Initiated Janney Neutral
Mar-05-18Initiated William Blair Outperform
Feb-22-18Reiterated Cantor Fitzgerald Underweight $122 → $113
Jan-25-18Downgrade Leerink Partners Outperform → Mkt Perform
Dec-21-17Initiated Oppenheimer Perform
Dec-13-17Reiterated Barclays Overweight $162 → $209
Dec-13-17Downgrade Maxim Group Buy → Hold $200
Dec-11-17Upgrade Jefferies Hold → Buy $130 → $211
Dec-11-17Reiterated Goldman Buy $186 → $309
Dec-11-17Reiterated Cantor Fitzgerald Underweight $58 → $113
Dec-05-17Initiated Canaccord Genuity Buy $202
Nov-30-17Reiterated Maxim Group Buy $170 → $200
Feb-14-19 07:55AM  Report: Exploring Fundamental Drivers Behind Tyson Foods, ElectraMeccanica Vehicles, Cousins Properties, Spirit Aerosystems, bluebird bio, and Yext New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Feb-13-19 10:31AM  Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline Zacks
Feb-12-19 09:11AM  AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma Zacks
Feb-11-19 06:30AM  bluebird bio Appoints Chip Baird as Chief Financial Officer Business Wire
Feb-06-19 01:52PM  Regeneron Q4 Earnings & Sales Beat on Strong Dupixent, Eylea Zacks
Feb-01-19 02:11PM  German firm that serves gene therapy biotechs opens Cambridge HQ American City Business Journals
Jan-31-19 11:46AM  Celgene (CELG) Q4 Earnings Beat Estimates, Revenues Up Y/Y Zacks
07:55AM  Today's Research Reports on Trending Tickers: bluebird bio and Mirati Therapeutics ACCESSWIRE
Jan-28-19 11:52AM  Did bluebird bio, Inc. (NASDAQ:BLUE) Insiders Sell Shares? Simply Wall St.
Jan-24-19 10:51AM  The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio Zacks
10:12AM  Where Will bluebird bio Be in 5 Years? Motley Fool
Jan-23-19 10:48AM  5 Best Biotech Bets Likely to Outperform Estimates in Q4 Zacks
Jan-22-19 11:50AM  Here's Why CRISPR Therapeutics Stock Fell Today Motley Fool
Jan-21-19 02:00PM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Jan-12-19 09:41AM  Here's What Pushed bluebird bio Stock Down 44.3% in 2018 Motley Fool
07:31AM  3 Biotech Stocks to Watch in 2019 Motley Fool
Jan-11-19 09:56AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Investigation Against bluebird bio, Inc. (BLUE) ACCESSWIRE
06:55AM  Today's Research Reports on Trending Tickers: bluebird bio and Ultragenyx Pharmaceutical ACCESSWIRE
Jan-10-19 08:01AM  Three tech, three biotech companies that are top takeover targets in 2019 MarketWatch +6.03%
Jan-08-19 07:33PM  Biotech Proposes Paying for Pricey Drugs by Installment The Wall Street Journal
05:44PM  Biotech Proposes Paying for Pricey Drugs by Installment The Wall Street Journal
05:31PM  Celgene (CELG) Provides Guidance for 2019, Updates Pipeline Zacks
Jan-07-19 08:00AM  bluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies Business Wire +6.67%
Jan-04-19 12:16PM  Here's Why bluebird bio Shares Got Knocked Down 19.3% in December Motley Fool +6.66%
10:13AM  Bristol-Myers Becomes a Cancer-Fighting Giant With Celgene Buyout InvestorPlace
10:01AM  Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus Zacks
Jan-03-19 10:30AM  ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
08:00AM  bluebird bio to Present at the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-28-18 01:59PM  Lifshitz & Miller LLP Announces Investigation of Bluebird Bio, Inc., Cavco Industries, Inc., Edge Therapeutics, Inc., Inuvo, Inc., Lumentum Holdings, Inc., National Commerce Corporation, and Nobilis Health Corp. PR Newswire
Dec-27-18 01:00PM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
12:30PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of bluebird bio, Inc. (BLUE) ACCESSWIRE
Dec-26-18 10:24AM  INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire +8.39%
Dec-24-18 03:35PM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
01:40PM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against bluebird bio, Inc. BLUE Business Wire
Dec-20-18 11:10AM  Bluebird Bio's Competitive Advantage Is Underappreciated, Raymond James Says In Bullish Initiation Benzinga -5.85%
Dec-19-18 08:23AM  Forget bluebird bio, Amgen Is a Better Biotech Stock Motley Fool
Dec-18-18 04:36PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Bluebird Bio, Inc. Investors (BLUE) Business Wire
Dec-17-18 12:46PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Bluebird Bio, Inc. Investors (BLUE) Business Wire
Dec-14-18 11:43AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of bluebird bio, Inc. GlobeNewswire
Dec-13-18 02:14PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Bluebird Bio, Inc. Investors (BLUE) Business Wire -5.40%
Dec-12-18 06:42PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Bluebird Bio, Inc. Investors (BLUE) Business Wire
08:11AM  bluebird bio, Inc. (NASDAQ:BLUE): Financial Strength Analysis Simply Wall St.
Dec-10-18 04:31PM  Why CRSP Stock Has Added Layers of Risk InvestorPlace
12:53PM  Is bluebird bio Inc (BLUE) A Good Stock To Buy? Insider Monkey
Dec-07-18 05:59PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of bluebird bio, Inc. BLUE GlobeNewswire -6.08%
Dec-06-18 08:56AM  Dow Drops 352 Points Because This Is Way More Than a Trade War Barrons.com
Dec-05-18 04:42PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. - BLUE PR Newswire
11:25AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of bluebird bio, Inc. (BLUE) GlobeNewswire
09:10AM  Biotech Stock Roundup: ASH Meet in Focus, Gilead's Drugs Get Approval in China Zacks
08:17AM  Can Celgene and bluebird bio Survive a Two-Pronged Attack? Motley Fool
Dec-04-18 08:13AM  Global Blood Therapeutics' Voxelotor on Faster Approval Path Zacks
06:50AM  Today's Research Reports on Trending Tickers: GlaxoSmithKline and bluebird bio ACCESSWIRE
12:20AM  Amgen antibody shows promise in myeloma trial, gets FDA fast track Reuters
Dec-03-18 09:15PM  bluebird bio Presents New Data for LentiGlobin Gene Therapy in Transfusion Dependent -Thalassemia at 60th Annual Meeting of the American Society of Hematology Business Wire -5.20%
09:15PM  bluebird bio Presents New Data for LentiGlobin Gene Therapy in Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology Business Wire
06:09PM  Celgene (CELG) Announces Various Cancer Data at ASH 2018 Zacks
Dec-02-18 07:30PM  bluebird bio and Celgene Corporation Present Initial Data from Ongoing Phase 1 Clinical Study of Next-Generation Anti-BCMA CAR T Cell Therapy bb21217 in Patients with Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting Business Wire
Dec-01-18 05:00PM  bluebird bio Presents Updated Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent -Thalassemia and Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology Business Wire
Nov-30-18 08:00AM  bluebird bio to Host Live Webcast of Investor and Analyst Event at the 60th Annual Meeting of the American Society of Hematology Business Wire
Nov-28-18 04:22PM  3 Themes To Watch As Biopharmas 'Bring Some Excitement' In Blood Cancer Investor's Business Daily
04:07PM  Celgene & Bluebird's CAR T Therapy Study Completes Enrollment Zacks
01:05PM  Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns' Benzinga
08:22AM  Biotech Stock Roundup: Pipeline Updates From CELG & VRTX, ZFGN Plunges on Hold News Zacks
Nov-19-18 04:13PM  3 High-Growth Stocks That Are Just Getting Started Motley Fool
Nov-18-18 09:51PM  Edited Transcript of BLUE earnings conference call or presentation 2-Nov-18 12:00pm GMT Thomson Reuters StreetEvents
Nov-17-18 08:31AM  My Top 3 Favorite Clinical-Stage Biotech Stocks to Buy Motley Fool
Nov-16-18 08:40AM  Market Trends Toward New Normal in PlayAGS, BEST, Inc. Sponsored ADR, Verrica Pharmaceuticals, Telenav, bluebird bio, and CompX International Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
07:00AM  Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and bluebird bio ACCESSWIRE
Nov-15-18 08:00AM  bluebird bio to Present at the Evercore ISI HealthCONx Conference Business Wire +5.40%
Nov-09-18 04:32PM  Waiting for bluebird bio to Sing at ASH Motley Fool
Nov-07-18 10:32PM  Here's Why bluebird bio Fell 21.4% in October Motley Fool
09:16AM  3 Cancer Stocks to Watch in December Motley Fool
08:24AM  3 Top Biotech Stocks to Buy in November Motley Fool
Nov-06-18 06:55AM  Today's Research Reports on Trending Tickers: bluebird bio and Geron ACCESSWIRE
Nov-05-18 12:09PM  Janney Upgrades bluebird bio Ahead Of Sickle Cell Presentation Benzinga
Nov-02-18 10:17AM  bluebird (BLUE) Q3 Loss Narrower Than Expected, Revenues Beat Zacks
Nov-01-18 06:20PM  Bluebird Bio (BLUE) Reports Q3 Loss, Tops Revenue Estimates Zacks +13.47%
05:18PM  Here's Why bluebird bio Jumped 13.5% Today Motley Fool
05:14PM  Bluebird: 3Q Earnings Snapshot Associated Press
04:00PM  bluebird bio Reports Third Quarter 2018 Financial Results and Highlights Operational Progress Business Wire
09:00AM  bluebird bio to Present New Data from Early- and Late-Stage Pipeline of Investigational Gene and Cell Therapies at the American Society of Hematology Annual Meeting Business Wire
Oct-31-18 08:00AM  Today's Research Reports on Trending Tickers: bluebird bio and Sarepta Therapeutics ACCESSWIRE
Oct-26-18 08:34AM  Here's Why I'm Not Selling My Celgene Shares Motley Fool
Oct-11-18 01:41PM  Here's Why bluebird bio Dropped 13.3% in September Motley Fool
Oct-05-18 05:00AM  bluebird bio Announces European Medicines Agencys Acceptance of Marketing Authorization Application for LentiGlobin Gene Therapy for the Treatment of Transfusion-Dependent -Thalassemia Business Wire
Oct-01-18 08:00AM  bluebird bio to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology Business Wire
Sep-28-18 08:30AM  Today's Research Reports on Trending Tickers: bluebird bio and Regeneron Pharmaceuticals ACCESSWIRE
Sep-25-18 03:59PM  Bullish Divergences on Bluebird Bio Tell Me This Stock Can Sing TheStreet.com
Sep-14-18 10:15AM  Why bluebird and Celgene Should Worry About Amgen's Latest Clinical Victory Motley Fool
Sep-12-18 06:00PM  Bluebird Bio Stock May Have Upside of at Least 60 Percent InvestorPlace
Sep-07-18 08:00AM  Today's Research Reports on Trending Tickers: bluebird bio and PTC Therapeutics ACCESSWIRE
Sep-05-18 08:28AM  The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results Benzinga
06:11AM  bluebird bio Presents Updated Data from Phase 2/3 Starbeam Study of Investigational Lenti-D Gene Therapy for CALD and Initial Data from Observational Study ALD-103 of Allogeneic Hematopoietic Stem Cell Transplant in CALD at 2018 SSIEM Business Wire
Aug-30-18 06:06PM  Software and Biotech Are Eating the World Zacks
Aug-29-18 08:00AM  bluebird bio to Present at Investor Conferences in September Business Wire
Aug-28-18 08:00AM  Today's Research Reports on Trending Tickers: Exelixis and bluebird bio ACCESSWIRE
Aug-27-18 12:14PM  Play The Future of Gene Therapy With These 5 Biotech Stocks InvestorPlace
Aug-23-18 05:47PM  East Bay biotech's different approach to cancer leads to $80 million IPO American City Business Journals
03:48PM  Lake Union biotech leases signal resurgence of life science market American City Business Journals
06:30AM  bluebird bio and Gritstone Oncology Announce Strategic Collaboration to Develop Novel Cancer Cell Therapies Business Wire
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy; Inhibrx, Inc. to research, develop, and commercialize CAR T Cell immunotherapies; and Gritstone Oncology, Inc. to research, develop, and commercialize products for the treatment of cancer using cell therapy, as well as a partnership agreement with Celgene European Investment Company LLC. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Walsh Jeffrey T.Chief Financial andFeb 08Option Exercise24.471,50036,70542,421Feb 12 04:11 PM
Walsh Jeffrey T.Chief Financial andFeb 08Sale131.291,500196,92840,921Feb 12 04:11 PM
Gregory Philip DChief Scientific OfficerFeb 05Option Exercise64.021,30083,22634,892Feb 07 05:21 PM
Gregory Philip DChief Scientific OfficerFeb 05Sale137.991,800248,38333,092Feb 07 05:21 PM
Davidson DavidChief Medical OfficerFeb 04Option Exercise31.664,910155,43236,526Feb 05 05:58 PM
Davidson DavidChief Medical OfficerFeb 04Sale134.304,910659,41731,616Feb 05 05:58 PM
WENTWORTH KORY JAMESPrincipal Accounting OfficerJan 28Sale125.9620926,3264,403Jan 30 04:35 PM
Davidson DavidChief Medical OfficerJan 18Option Exercise24.472,03549,79624,276Jan 23 04:18 PM
Davidson DavidChief Medical OfficerJan 18Sale130.052,035264,64422,241Jan 23 04:18 PM
Gregory Philip DChief Scientific OfficerJan 16Option Exercise75.601,400105,84028,742Jan 18 04:03 PM
Walsh Jeffrey T.Chief FinancialJan 16Option Exercise24.473,00073,41035,483Jan 18 04:06 PM
Walsh Jeffrey T.Chief FinancialJan 16Sale125.143,000375,42832,483Jan 18 04:06 PM
Gregory Philip DChief Scientific OfficerJan 16Sale124.251,900236,06926,842Jan 18 04:03 PM
Gregory Philip DChief Scientific OfficerJan 07Option Exercise50.5160030,30631,221Jan 09 04:57 PM
Walsh Jeffrey T.Chief FinancialJan 07Sale113.643,012342,27632,483Jan 09 05:05 PM
Leschly NickPresident and CEOJan 07Sale113.647,374837,966193,203Jan 09 05:03 PM
Gregory Philip DChief Scientific OfficerJan 07Sale112.493,879436,36327,342Jan 09 04:57 PM
FINGER ALISON CECILYChief Commercial OfficerJan 07Sale113.6464373,06814,548Jan 09 04:53 PM
Davidson DavidChief Medical OfficerJan 07Sale113.642,664302,73422,241Jan 09 04:46 PM
Cole JasonChief Legal OfficerJan 07Sale113.641,416160,91420,194Jan 09 04:39 PM
Davidson DavidChief Medical OfficerJan 03Option Exercise24.471002,44725,005Jan 04 04:17 PM
FINGER ALISON CECILYChief Commercial OfficerJan 03Sale99.3142842,50615,239Jan 07 04:39 PM
Davidson DavidChief Medical OfficerJan 03Sale100.3210010,03224,905Jan 04 04:17 PM
Davidson DavidChief Medical OfficerJan 02Option Exercise17.397,500130,41029,605Jan 04 04:17 PM
Davidson DavidChief Medical OfficerJan 02Sale98.807,500741,02824,905Jan 04 04:17 PM
WENTWORTH KORY JAMESPrincipal Accounting OfficerDec 19Sale103.0538839,9834,612Dec 21 04:26 PM
Gregory Philip DChief Scientific OfficerDec 06Option Exercise50.5160030,30631,471Dec 10 04:09 PM
HIGH SUSANNA GATTIChief Operating OfficerDec 06Sale105.711,875198,19813,735Dec 10 04:11 PM
Gregory Philip DChief Scientific OfficerDec 06Sale106.5685090,57730,621Dec 10 04:09 PM
Davidson DavidChief Medical OfficerDec 04Option Exercise5.502,00011,00126,905Dec 06 04:12 PM
Davidson DavidChief Medical OfficerDec 04Sale121.052,000242,10824,905Dec 06 04:12 PM
Davidson DavidChief Medical OfficerDec 03Option Exercise5.506,00033,00230,905Dec 06 04:12 PM
HIGH SUSANNA GATTIChief Operating OfficerDec 03Sale113.831,890215,13515,610Dec 06 04:14 PM
Davidson DavidChief Medical OfficerDec 03Sale113.596,000681,53824,905Dec 06 04:12 PM
Walsh Jeffrey T.Chief FinancialNov 09Option Exercise24.471,50036,70536,995Nov 14 04:10 PM
Walsh Jeffrey T.Chief FinancialNov 09Sale130.591,500195,89135,495Nov 14 04:10 PM
Gregory Philip DChief Scientific OfficerNov 05Option Exercise64.021,30083,22632,671Nov 07 04:14 PM
Gregory Philip DChief Scientific OfficerNov 05Sale137.381,800247,27730,871Nov 07 04:14 PM
Davidson DavidChief Medical OfficerNov 02Option Exercise5.505,00027,50229,905Nov 06 04:15 PM
Davidson DavidChief Medical OfficerNov 02Sale133.645,000668,21624,905Nov 06 04:15 PM
Walsh Jeffrey T.Chief FinancialOct 10Option Exercise24.471,50036,70536,995Oct 12 04:53 PM
Walsh Jeffrey T.Chief FinancialOct 10Sale135.231,500202,83935,495Oct 12 04:53 PM
Gregory Philip DChief Scientific OfficerOct 05Option Exercise64.021,30083,22633,171Oct 10 04:17 PM
Gregory Philip DChief Scientific OfficerOct 05Sale140.561,800253,00031,371Oct 10 04:17 PM
Davidson DavidChief Medical OfficerOct 02Option Exercise5.505,00027,50229,905Oct 04 04:21 PM
Davidson DavidChief Medical OfficerOct 02Sale139.325,000696,58824,905Oct 04 04:21 PM
Walsh Jeffrey T.Chief FinancialSep 10Option Exercise24.471,50036,70536,995Sep 12 04:12 PM
Walsh Jeffrey T.Chief FinancialSep 10Sale150.161,500225,24335,495Sep 12 04:12 PM
Mandell JamesDirectorSep 10Sale150.771,000150,7711,000Sep 12 04:07 PM
Gregory Philip DChief Scientific OfficerSep 05Option Exercise64.021,30083,22633,671Sep 07 04:32 PM
Gregory Philip DChief Scientific OfficerSep 05Sale163.021,800293,44131,871Sep 07 04:32 PM
Davidson DavidChief Medical OfficerSep 04Option Exercise5.507,00038,50331,905Sep 06 04:12 PM
Davidson DavidChief Medical OfficerSep 04Sale166.647,0001,166,49324,905Sep 06 04:12 PM
Walsh Jeffrey T.Chief FinancialAug 30Option Exercise10.8820,000217,68955,495Sep 04 05:03 PM
Walsh Jeffrey T.Chief FinancialAug 30Sale175.4020,0003,507,94835,495Sep 04 05:03 PM
FINGER ALISON CECILYChief Commercial OfficerAug 20Sale158.0725940,94015,667Aug 22 06:32 AM
Walsh Jeffrey T.Chief FinancialAug 10Option Exercise5.501,5008,25136,995Aug 14 04:47 PM
Walsh Jeffrey T.Chief FinancialAug 10Sale156.931,500235,38935,495Aug 14 04:47 PM
Cole JasonChief Legal OfficerAug 08Option Exercise22.534,43899,98821,610Aug 10 06:48 AM
Gregory Philip DChief Scientific OfficerAug 06Option Exercise64.021,30083,22634,171Aug 08 04:06 PM
Gregory Philip DChief Scientific OfficerAug 06Sale156.611,800281,88932,371Aug 08 04:06 PM
Davidson DavidChief Medical OfficerAug 02Option Exercise5.507,00038,50331,905Aug 06 04:08 PM
Walsh Jeffrey T.Chief FinancialAug 02Option Exercise5.5021,500118,25956,995Aug 06 04:10 PM
Walsh Jeffrey T.Chief FinancialAug 02Sale152.0221,5003,268,49335,495Aug 06 04:10 PM
Davidson DavidChief Medical OfficerAug 02Sale150.377,0001,052,58524,905Aug 06 04:08 PM
Davidson DavidChief Medical OfficerJul 11Option Exercise5.503,00016,50127,905Jul 13 04:31 PM
Davidson DavidChief Medical OfficerJul 11Sale180.153,000540,44324,905Jul 13 04:31 PM
Cole JasonChief Legal OfficerJul 09Sale170.255,126872,71517,172Jul 11 04:10 PM
Davidson DavidChief Medical OfficerJul 02Option Exercise5.5010,00055,00434,905Jul 03 04:10 PM
Davidson DavidChief Medical OfficerJul 02Sale153.9610,0001,539,60424,905Jul 03 04:10 PM
Gregory Philip DChief Scientific OfficerJun 18Sale178.413,901695,97825,371Jun 20 04:29 PM
Vachon MarkDirectorJun 14Sale189.991,000189,9920Jun 18 04:43 PM
HIGH SUSANNA GATTIChief Operating OfficerJun 04Option Exercise68.653,500240,27521,000Jun 06 04:36 PM
Davidson DavidChief Medical OfficerJun 04Option Exercise24.4713,000318,11037,905Jun 06 04:39 PM
Vachon MarkDirectorJun 04Option Exercise42.076,000252,4207,000Jun 06 04:42 PM
Vachon MarkDirectorJun 04Sale188.226,0001,129,3011,000Jun 06 04:42 PM
Davidson DavidChief Medical OfficerJun 04Sale187.8413,0002,441,96524,905Jun 06 04:39 PM
HIGH SUSANNA GATTIChief Operating OfficerJun 04Sale199.113,500696,89217,500Jun 06 04:36 PM
Cole JasonChief Legal OfficerMay 04Sale170.893,750640,84922,298May 08 04:18 PM
Davidson DavidChief Medical OfficerMay 02Option Exercise24.4713,000318,11037,905May 04 04:39 PM
Davidson DavidChief Medical OfficerMay 02Sale177.5213,0002,307,69624,905May 04 04:39 PM
Davidson DavidChief Medical OfficerApr 12Option Exercise24.473,00073,41027,905Apr 16 04:48 PM
Davidson DavidChief Medical OfficerApr 12Sale180.173,000540,50824,905Apr 16 04:48 PM
Davidson DavidChief Medical OfficerApr 02Option Exercise24.4722,000538,34046,905Apr 04 04:47 PM
Gregory Philip DChief Scientific OfficerApr 02Option Exercise50.511,25063,13831,522Apr 04 04:50 PM
Gregory Philip DChief Scientific OfficerApr 02Sale168.712,250379,60829,272Apr 04 04:50 PM
Davidson DavidChief Medical OfficerApr 02Sale167.5222,0003,685,38724,905Apr 04 04:47 PM
Vachon MarkDirectorMar 15Option Exercise30.476,000182,8207,000Mar 19 04:06 PM
Vachon MarkDirectorMar 15Sale214.386,0001,286,2501,000Mar 19 04:06 PM
Davidson DavidChief Medical OfficerMar 02Option Exercise5.504,00022,00228,905Mar 06 04:29 PM
Davidson DavidChief Medical OfficerMar 02Sale201.194,000804,75124,905Mar 06 04:29 PM
Gregory Philip DChief Scientific OfficerMar 01Option Exercise50.511,25063,13832,522Mar 05 05:14 PM
Gregory Philip DChief Scientific OfficerMar 01Sale200.002,250449,99530,272Mar 05 05:14 PM
HIGH SUSANNA GATTIChief Operating OfficerFeb 28Option Exercise68.651,04471,67118,544Mar 02 04:01 PM
HIGH SUSANNA GATTIChief Operating OfficerFeb 28Sale202.671,044211,59217,500Mar 02 04:01 PM
open in yahoo | open in reuters | open in google